“…Advantages and disadvantages of macrocyclic DOTA, NOTA, and their related chelating groups, DOTAGA, α-(2-carboxyethyl)-1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraaceticacid, NOTAGA, 1,4,7-triazacyclononane-1-glutaric acid-4,7-acetic acid, , etc., have been reviewed. − In addition, series of acyclic chelators, DTPA, HBED, AAZTA, etc., , have been reported. Many DOTA and DTPA derivatives have been successfully developed in recent years as new chelating agents by which forming stable metal complexes with enhanced properties for radiopharmaceuticals. ,,− Originally, AAZTA (6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid), a heptadentate chelator, was first reported by Aime et al designed to form gadolinium (Gd) complexes as MRI contrast imaging agents. It was reported that AAZTA is also a promising chelator for gallium-68 or scandium-44. , Promising AAZTA-based bifunctional chelators for preparation of analogs of [ 68 Ga]Ga-DOTA-TOC (NETSOPT), [ 68 Ga/ 44 Sc/ 177 Lu]Ga/Sc/Lu-AAZTA-TOC. , as well as [ 68 Ga]Ga-AAZTA-PSMA derivatives were prepared and evaluated.…”